Introduction
Rising cancer rates are an increasing challenge in the treatment of persons living with human immunodeficiency virus (PLWHIV) [1] [2] [3] . Lung cancer (LC) is one of the most common non-AIDS (acquired immune deficiency syndrome)-defining cancers (NADC) [2, 4, 5] and has recently become a leading cause of death in PLWHIV in high-income countries [6] . As LC incidence is linked to age, it is likely to become even more frequent with the increasing lifespan of PLWHIV under effective combination antiretroviral therapy (cART).
This article gives an overview of the current knowledge on LC in PLWHIV along with recommendations for diagnosis and treatment.
Epidemiology
Several studies have shown an increased incidence of LC in PL-WHIV when compared to the general population [5, [7] [8] [9] [10] [11] [12] , even after the establishment of effective cART (table1) [13] [14] [15] [16] [17] [18] . A study from the UK that included 8,400 PLWHIV with LC diagnosed between 1986 and 2001 reported a 6.7-fold (95% confidence interval (CI) 3.1-13.9) increased risk of LC in the cART era as compared to pre-cART prior to 1996 (0.8, 95% CI 0.2-3.2) [19] . The increased incidence can likely be explained by the considerably longer survival rates of PLWHIV under cART, allowing for the development of LC. Interestingly, a more recent analysis of the French Hospital Database showed a steady fall of LC rates since 1996, following the trend of declining smoking rates in the general population [20] . Moreover, the occurrence of LC in PLWHIV has been shown almost exclusively in smokers [4, 21] , with the risk rising significantly with 10 and more pack-years [22] . Indeed, the prevalence of smoking is known to be particularly high in the HIV-positive population [23] [24] [25] [26] . Nevertheless, 2 studies focusing on the impact of
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Summary
Lung cancer (LC) is one of the most common non-AIDS (acquired immune deficiency syndrome)-defining malignancies. It occurs more frequently in persons living with human immunodeficiency virus (PLWHIV) than in the HIV-negative population. Compared to their HIVnegative counterparts, patients are usually younger and diagnosed at more advanced stages. The pathogenesis of LC in PLWHIV is not fully understood, but immunosuppression in combination with chronic infection and the oncogenic effects of smoking and HIV itself all seem to play a role. Currently, no established preventive screening is available, making smoking cessation the most promising preventive measure. Treatment protocols and standards are the same as for the general population. Notably, immuno-oncology will also become standard of care in a significant subset of HIV-infected patients with LC. As drug interactions and hematological toxicity must be taken into account, a multidisciplinary approach should include a physician experienced in the treatment of HIV. Only limited data is available on novel targeted therapies and checkpoint inhibitors in the setting of HIV.
smoking also showed an independent association between HIV and LC with an incidence rate ratio of 1.7 (95% CI 1.5-1.9) [27] and a hazard ratio of 3.6 (95% CI 1.6-7.9) [28] .
Pathogenesis
The specific mechanism accelerating the development of LC in PLWHIV is not completely understood, but a multifactorial genesis seems to be causal. The reduced immune surveillance due to the HIV infection along with the oncogenic effect of chronic infections and tobacco use might be pivotal. The association of immunosuppression with an elevated incidence of cancer has been described in several studies. For example, a large US population registry analysis matching cancer and AIDS demonstrated significantly higher rates of cancer, including LC, associated with immunosuppression [29] . Accordingly, studies comparing immunosuppression in PLWHIV and organ transplant recipients showed a similar increase in cancer rates in both groups, even though patterns differed in parts depending on the type of transplant [30, 31] . As expected, excess risk was mostly attributable to virus-related cancers. An oncogenic effect of the virus itself is under discussion, as study results described HIV replication to promote proliferation and metastasis of LC as well as downregulate the tumor suppressor gene p53 [32] [33] [34] . Regardless of the agent, chronic pulmonary inflammation seems to be a risk factor for LC. Elevated inflammation markers have already been shown to be associated with the development of LC in the general population [35, 36] , and PLWHIV with chronic pneumonia or bronchial asthma are recognized as being at high risk for LC [22, 28, 37] .
In contrast, no significant risk reduction for LC has been observed so far with higher CD4 counts [4, 38] . The still limited immune reconstitution after initiation of cART, the chronic persistence of the virus, and the increased lifespan of PLWHIV are the most likely reasons why LC rates remain high in the HIV-positive population. Nonetheless, a French long-term retrospective analysis of NADC between 1997 and 2009 showed that even though the risk of LC was higher in PLWHIV than in the general population, in patients with restored immune systems under cART with a CD4 count of over 500/μl for 2 years it matched that of the non-HIVinfected population [20] . If this trend is proven to be consistent in the future, cART must also be considered, in contrast to former assumptions, as an effective preventive measure against LC, in addition to smoking cessation.
Clinical Characteristics
PLWHIV suffering from LC are on average 10-15 years younger and have more advanced disease at the time of diagnosis than patients without HIV (table 2) [27, [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] . The reasons for this can most likely be found in the above described pathogenesis, as well as the repeatedly noted earlier and more excessive tobacco use in PLWHIV [42, 50, 51] .
The distribution of histological types does not substantially differ from the general population, with adenocarcinoma being the most common, followed by squamous cell carcinoma (SCC), small cell carcinoma (SCLC), large cell carcinoma, and others (table 2). The prevalence of SCC appears to be higher, and that of SCLC lower, in PLWHIV as compared to the HIV-negative population. However, this may be the result of summarizing data from various studies with differences in design and patient numbers. The largest study comparing 457 HIV-infected LC cases with 614 uninfected cases did not find significant differences in the distribution of histological types [27] .
Even though pre-cART data suggested poorer prognosis for PL-WHIV with LC [52] [53] [54] [55] , studies focusing in the post-cART era after 1996 found no significant differences in survival rates for PL-WHIV [8, 43, 44, 47, 56] . The improved outcome is most likely related, in part, to the better overall health of PLWHIV, but also to the better care since having overcome several uncertainties and worries of the first years of the HIV epidemic.
Prevention
Despite the evidently elevated LC risk in PLWHIV, routine prevention remains a challenging task. Studies testing routine thoracic radiography or cytology of sputum in HIV-negative high-risk individuals (heavy smokers) have not shown a survival benefit in the past [57, 58] . To overcome these limitations, a large multicenter study compared LC survival benefit using low-dose computed tomography (LDCT) screening with conventional radiography in over 54,000 persons with a high risk profile (55-74 years of age and at least 30 pack-years). LC-related survival was 20% higher in the LDCT group (7% total survival benefit) [59, 60] . In view of the high risk profile of smoking HIV-positive individuals, 2 studies [14] 54,780 3.3 2.8-3.9 Engels et al. [15] 5,238 4.7 3.2-6.5 Long et al. [16] 2,566 5.5 3.7-8.0 Dal Maso et al. [17] 21,951 4.1 2.9-5.5 Chaturvedi et al. [18] 397,927 3.8 3.6-4.1 tested the survival benefit using routine LDCT scans in PLWHIV. The results of the first study screening 224 heavily smoking PL-WHIV did not show a clinical advantage, finding only 1 LC case per 678 person-years, which was markedly below the results of an earlier study [61] . The younger age (median 48 years) of the participants might have contributed to this outcome, but given the described younger age at LC onset in PLWHIV, this explanation seems rather unsatisfactory. In contrast, the second study with 442 heavily smoking PLWHIV with a history of immunodeficiency was able to detect 9 LC cases during a 2-year follow-up using CT scan [62] . Most of the patients were under 55 years of age, and 6 of 10 LC were diagnosed at an early stage. The authors concluded that CT screening of the above patient group is feasible, safe, and effective. Nonetheless, more studies are needed to establish the impact on outcome, quality of life, and cost-effectiveness.
Smoking cessation remains the most effective measure to prevent LC in PLWHIV. The importance of smoking cessation cannot be overemphasized, especially considering the results of a Danish study demonstrating that PLWHIV lose more life years through the consumption of tobacco than through the HIV infection itself [63] . Tobacco cessation itself is, however, challenging, also for PL-WHIV, and special interventions for this population could only moderately elevate abstinence rates [64] . Parts of the target group might also not be eligible for any preventive measures, given the results of a large Spanish study showing that 58% of LC in HIVpositive persons occurred in intravenous drug users, only 67% were actively on cART, and the median CD4 count at the time of LC diagnosis was 237/mm 3 (range 85-397/mm 3 ), implying insufficient adherence to therapy [11] .
Treatment
Treatment of LC does not generally differ between HIV-positive and -negative patients, including the consideration of the general physical condition for treatment planning. In a curative treatment situation, the HIV infection itself should not be a contraindication for oncological surgery or curative chemo-and/or radiotherapy if the patient is adequately fit for such an intervention. Chemotherapy is generally tolerated with common side effects. Nevertheless, HIV medication has to be reevaluated in consideration of the antineoplastic agents of choice because of potential drug interactions (see also article about drug interactions). Particularly, boostered antiretroviral agents should be carefully selected because of possible adverse events in combination with chemotherapy for LC such as vinca alkaloids and taxanes, and because of their severe hematotoxic effects [65, 66] . Bearing this in mind, data clearly show improved survival with early and effective antiretroviral therapy [45, 66] .
The identification of multiple genetic driver mutations (e.g. EGFR, ALK, MET, ROS-1) and the subsequent introduction of targeted therapies are a milestone in the treatment of LC. Applicability, drug compatibility, and treatment effects are therefore of imperative interest for the HIV-positive population. Unfortunately, PLWHIV were normally excluded from phase I-III studies. First preliminary reports about EGFR mutations have not demonstrated a difference in genetic epidemiology or treatment outcome between HIV-positive and -negative patients [67, 68] , but more data is needed on this matter.
To our knowledge, no published data is available regarding the treatment of PLWHIV with the programmed cell death protein 1 (PD-1) inhibitor or its ligand (PD-L-1), even though this new therapeutic approach to LC treatment might be of special interest in this population. PD-1 inhibition not only re-enables the immune system to recognize cancer cells [69] , but the blockade of this molecule might also facilitate recovery of a dysfunctional immune system in the case of HIV infection. PD-1 is expressed on T-cells (CD4, CD8, natural killer), B-cells, and monocytes during infection, leading to cellular immune depletion over time. Inhibition restores the virus-specific function of T-and B-cells, increasing the production of antibodies [70] . Hence, having more specific data on these novel agents in the therapy of PLWHIV is of pressing importance and interest. In Germany, a registry of HIV-infected patients treated with checkpoint inhibitors is planned.
In conclusion, to obtain the best possible care, the diagnosis and treatment of LC in PLWHIV should be led by a multidisciplinary team, as is done in HIV-negative patients, which should include a physician experienced in HIV treatment. Intensified collaboration with a certified LC center seems advisable. With the exception of possible drug interactions, there are no known exclusion criteria for any of the therapeutic options. Apart from performing CD4 cell counts and HIV RNA tests, clinical, biochemical, and pathological assessments before administering antineoplastic chemotherapy or immunotherapy do not differ from those in HIV-negative patients. In the case of a simultaneous diagnosis of LC and HIV, antiretroviral therapy should be started as early as possible after antineoplastic therapy is initiated and the patient is clinically stable. Should a patient already be under cART treatment, his/her medication should be continued and, if necessary, adjusted according to potential drug interactions.
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